(MENAFN- Investor Brand Network)
Psilocybin is the primary active compound found in hallucinogenic mushrooms. This compound usually turns into psilocin upon consumption. Recent research has provided evidence showing that psilocybin-assisted therapy may be effective in treating addiction, which has led others to wonder whether the psychedelic could also help individuals to control food cravings.
A 2021 study also found that individuals who had ingested a classic psychedelic at least once in their lives had a considerably lower chance of being obese or…
Read More>>
NOTE TO INVESTORS: The latest news and updates relating to Silo Pharma Inc. (OTC: SILOD) are available in the company's newsroom at
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text“Groovy” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published:
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
415.949.5050 Office
PsychedelicNewsWire is part of the InvestorBrandNetwork .
MENAFN23092022000224011066ID1104915552
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.